BlueCrest Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

BlueCrest Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,231	Closed	-$561K	–	171
2025 Q3	$561K	Buy	+1,231	New	+$501K	0.01%	165
2018 Q4	–	Sell	-3,377	Closed	-$296K	–	844
2018 Q3	$296K	Buy	+3,377	New	+$340K	0.01%	1047
2018 Q1	–	Sell	-4,529	Closed	-$575K	–	1463
2017 Q4	$575K	Sell	4,529 -11,426	-72%	-$1.44M	0.02%	496
2017 Q3	$1.88M	Sell	15,955 -392	-2%	-$33.5K	0.08%	262
2017 Q2	$1.3M	Buy	+16,347	New	+$1.04M	0.05%	418
2016 Q1	–	Sell	-4,460	Closed	-$420K	–	765
2015 Q4	$420K	Buy	+4,460	New	+$414K	0.02%	628

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlueCrest Capital Management's ALNY Position: Q4 2025 in Review

BlueCrest Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 1,231 shares — an estimated $561K sold.

BlueCrest Capital Management first reported a position in ALNY in Q4 2015 and held it in 6 quarters. The position peaked at $1.88M in Q3 2017. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

BlueCrest Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
BlueCrest Capital Management sold 1,231 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $561K.
BlueCrest Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2015 and held it in 6 quarters.
BlueCrest Capital Management's Alnylam Pharmaceuticals position peaked at $1.88M in Q3 2017.
851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on BlueCrest Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.